The following represents disclosure information provided by authors of this abstract. The program committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered compensated. Relationships are self-held unless otherwise noted. I = Immediate Family Member, Inst = My Institution
 
Open Payments is a public database containing information reported by companies about payments made to US-licensed physicians (Open Payments)
ER, PR, and HER2 expression in Ugandan breast cancer patients: An evaluation of in-country RT-PCR compared to IHC.
 
Manoj Menon
Research Funding - Cepheid (Inst); GlaxoSmithKline (Inst)
 
Jackson Orem
No Relationships to Disclose
 
Scott Adams
No Relationships to Disclose
 
Alex Bakenga
No Relationships to Disclose
 
Diana Basemera
No Relationships to Disclose
 
David Kasozi
No Relationships to Disclose
 
Eric Quentin Konnick
Honoraria - Clinical Care Options; Medscape; National Comprehensive Cancer Network; Roche; Ventana Medical Systems
Consulting or Advisory Role - River West Meeting Associates
Travel, Accommodations, Expenses - Clinical Care Options; Medscape; National Comprehensive Cancer Network; River West Meeting Associates; Roche; Ventana Medical Systems
 
Kelvin Mubiru
No Relationships to Disclose
 
Yusuf Mulumba
No Relationships to Disclose
 
Catherine Muwonge
No Relationships to Disclose
 
Lazarus Okoche
No Relationships to Disclose
 
Robert Pierce
Leadership - Alvaxa Biosciences (I)
Stock and Other Ownership Interests - Alvaxa Biosciences; Calithera Biosciences (I); Celgene (I); Five Prime Therapeutics (I); Immunomic Therapeutics; OncoSec; Sensei Biotherapeutics
Consulting or Advisory Role - Abbvie; Apros Therapeutics (I); Calithera Biosciences; Genexine (I); Ideaya Biosciences (I); IgM Biosciences (I); Immune Design (I); Juno Therapeutics (I); Neoleukin Therapeutics; Nkarta (I); Pulse Biosciences; Seagen (I)
Research Funding - AstraZeneca/MedImmune (Inst); Exicure (Inst); Immunomic Therapeutics (Inst); Incyte (Inst); Juno Therapeutics (Inst); Minerva Neurosciences (Inst); Pulse Biosciences (Inst); Sensei Biotherapeutics (Inst); X4 Pharma (Inst)
Travel, Accommodations, Expenses - Immunomic Therapeutics; Immunomic Therapeutics; Pulse Biosciences; Sensei Biotherapeutics
 
Julie Gralow
Consulting or Advisory Role - AstraZeneca; Genentech; Genomic Health; Immunomedics; Merck; Novartis; Pfizer; Puma Biotechnology; Sandoz
 
Nixon Niyonzima
No Relationships to Disclose